These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31978670)

  • 1. Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review.
    Fluyau D; Revadigar N; Pierre CG
    Drug Alcohol Depend; 2020 Mar; 208():107845. PubMed ID: 31978670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
    Bisaga A; Comer SD; Ward AS; Popik P; Kleber HD; Fischman MW
    Psychopharmacology (Berl); 2001 Aug; 157(1):1-10. PubMed ID: 11512037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia.
    McCartney CJ; Sinha A; Katz J
    Anesth Analg; 2004 May; 98(5):1385-400, table of contents. PubMed ID: 15105220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction.
    Herman BH; Vocci F; Bridge P
    Neuropsychopharmacology; 1995 Dec; 13(4):269-93. PubMed ID: 8747752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMDA receptor antagonists for the treatment of neuropathic pain.
    Collins S; Sigtermans MJ; Dahan A; Zuurmond WW; Perez RS
    Pain Med; 2010 Nov; 11(11):1726-42. PubMed ID: 21044263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
    Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
    Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
    Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
    Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of N-methyl-D-aspartate receptor antagonists in postoperative pain management.
    Suzuki M
    Curr Opin Anaesthesiol; 2009 Oct; 22(5):618-22. PubMed ID: 19535974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of NMDA-receptor antagonists in the treatment of chronic pain.
    Hewitt DJ
    Clin J Pain; 2000 Jun; 16(2 Suppl):S73-9. PubMed ID: 10870744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of memantine and ketamine in morphine- and pentazocine-induced antinociception in mice.
    Malec D; Mandryk M; Fidecka S
    Pharmacol Rep; 2008; 60(2):149-55. PubMed ID: 18443375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha2-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell MF; Ali R; White JM
    Cochrane Database Syst Rev; 2014 Mar; (3):CD002024. PubMed ID: 24683051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Iwata N
    J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database.
    Revol B; Lapeyre-Mestre M; Fouilhé Sam-Laï N; Jouanjus E
    Br J Clin Pharmacol; 2022 Nov; 88(11):4937-4940. PubMed ID: 35665950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
    Vanle B; Olcott W; Jimenez J; Bashmi L; Danovitch I; IsHak WW
    Transl Psychiatry; 2018 Jun; 8(1):117. PubMed ID: 29907742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NMDA receptor antagonists memantine and ketamine as anti-migraine agents.
    Podkowa K; Czarnacki K; Borończyk A; Borończyk M; Paprocka J
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1371-1398. PubMed ID: 36869904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent insights into the mode of action of memantine and ketamine.
    Johnson JW; Glasgow NG; Povysheva NV
    Curr Opin Pharmacol; 2015 Feb; 20():54-63. PubMed ID: 25462293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials.
    Sang CN; Booher S; Gilron I; Parada S; Max MB
    Anesthesiology; 2002 May; 96(5):1053-61. PubMed ID: 11981142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development.
    Elliott K; Kest B; Man A; Kao B; Inturrisi CE
    Neuropsychopharmacology; 1995 Dec; 13(4):347-56. PubMed ID: 8747759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice.
    Popik P; Kozela E; Danysz W
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):425-32. PubMed ID: 10763858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.